Assessing ImmunoResponse Post Eribulin: Eribulin and Immunogenicity in Advanced Breast Cancer

Clinical trial NCT05033769 · UNKNOWN

Trial details

NCT number: NCT05033769
Sponsor: Institut fuer Frauengesundheit
Status: UNKNOWN
Phase: Phase 4
Study type: INTERVENTIONAL

Breast Cancer Female Neoplasm, Breast Breast Cancer Metastatic

Start date: 2021-03-11
Primary completion: 2023-07-01
Enrollment: 82

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.